ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

NCT02858258 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

870

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: R-CHOP/R-DHAP
DRUG: Ibrutinib (Induction)
DRUG: ASCT conditioning
DRUG: Ibrutinib (Maintenance)

Sponsor

Prof. Dr. M. Dreyling (co-chairman)

Collaborators

[object Object]